Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

HF 2326

as introduced - 92nd Legislature (2021 - 2022) Posted on 03/22/2021 02:04pm

KEY: stricken = removed, old language.
underscored = added, new language.
Line numbers 1.1 1.2 1.3 1.4 1.5 1.6
1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23
2.24 2.25 2.26 2.27 2.28 2.29 2.30 3.1 3.2 3.3 3.4 3.5 3.6

A bill for an act
relating to human services; adding two members to the opioid prescribing working
group; changing requirements of annual prescribing reports related to the opioid
prescribing improvement program; amending Minnesota Statutes 2020, section
256B.0638, subdivisions 3, 7.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2020, section 256B.0638, subdivision 3, is amended to read:


Subd. 3.

Opioid prescribing work group.

(a) The commissioner of human services, in
consultation with the commissioner of health, shall appoint the following voting members
to an opioid prescribing work group:

(1) two consumer members who have been impacted by an opioid abuse disorder or
opioid dependence disorder, either personally or with family members;

(2) one member who is a licensed physician actively practicing in Minnesota and
registered as a practitioner with the DEA;

(3) one member who is a licensed pharmacist actively practicing in Minnesota and
registered as a practitioner with the DEA;

(4) one member who is a licensed nurse practitioner actively practicing in Minnesota
and registered as a practitioner with the DEA;

(5) one member who is a licensed dentist actively practicing in Minnesota and registered
as a practitioner with the DEA;

(6) two members who are nonphysician licensed health care professionals actively
engaged in the practice of their profession in Minnesota, and their practice includes treating
pain;

(7) one member who is a mental health professional who is licensed or registered in a
mental health profession, who is actively engaged in the practice of that profession in
Minnesota, and whose practice includes treating patients with chemical dependency or
substance abuse;

(8) one member who is a medical examiner for a Minnesota county;

(9) one member of the Health Services Policy Committee established under section
256B.0625, subdivisions 3c to 3e;

(10) one member who is a medical director of a health plan company doing business in
Minnesota;

(11) one member who is a pharmacy director of a health plan company doing business
in Minnesota; deleted text begin and
deleted text end

(12) one member representing Minnesota law enforcementdeleted text begin .deleted text end new text begin ; and
new text end

new text begin (13) two consumer members who are Minnesota residents and who have used or are
using opioids to manage chronic pain.
new text end

(b) In addition, the work group shall include the following nonvoting members:

(1) the medical director for the medical assistance program;

(2) a member representing the Department of Human Services pharmacy unit; and

(3) the medical director for the Department of Labor and Industry.

(c) An honorarium of $200 per meeting and reimbursement for mileage and parking
shall be paid to each voting member in attendance.

Sec. 2.

Minnesota Statutes 2020, section 256B.0638, subdivision 7, is amended to read:


Subd. 7.

Annual report to legislature.

By September 15deleted text begin , 2016, and annually thereafterdeleted text end new text begin
every year
new text end , the commissioner of human services shall report to the legislature on the
implementation of the opioid prescribing improvement program in the Minnesota health
care programs. The report mustnew text begin :
new text end

new text begin (1)new text end include data on the utilization of opioids within the Minnesota health care programsdeleted text begin .deleted text end new text begin
and contain monitoring protocols and data on patient impact and patient outcome, including
adverse events and unintended consequences from the program including from opioid
prescribing guidelines;
new text end

new text begin (2) outline safeguards implemented to prevent misapplication and misinterpretation of
any component of the opioid prescribing improvement program; and
new text end

new text begin (3) make any recommendations developed for improvements to the program or to end
the program, including any necessary statutory changes.
new text end